![](https://redarrowtx.com/wp-content/themes/redarrow/images/sub_head.jpg)
Our Science
Challenges of Drug Delivery Systems
- Stably/efficiently delivering biologics
- Precise delivery to target disease site
- Toxicity of payload/carrier material
Our Solution
Nanopolymers stably/efficiently load biologics in micelle form, preventing biologics from becoming active and causing toxicity off-target.
![](https://redarrowtx.com/wp-content/uploads/2023/06/image1.jpg)
pH change triggers nanopolymers to detach from biologics, resulting in precise biologics delivery to target disease site.
Detached PEG-based nanopolymers or micelles remaining in the bloodstream are metabolized with low safety concerns.
![](https://redarrowtx.com/wp-content/uploads/2023/06/image2.jpg)
Pipelines
The Problem with Existing Cancer Immunotherapy
![](https://redarrowtx.com/wp-content/uploads/2023/06/image4.jpg)
- Immunotherapy has potential to achieve complete cure of cancer.
![](https://redarrowtx.com/wp-content/uploads/2023/06/image5.jpg)
- Immunotherapies do not work for 80% of solid tumor patients.
Our Solution: NCM (Nanopolymer Cytokine Micelles)
IL-12-loaded NCM is systemically injected and travel through pores in cancer microvessels to the tumor microenvironment.
IL-12 is emitted in the tumor microenvironment and recruits immune cells, resulting in cancer cell death.
![](https://redarrowtx.com/wp-content/uploads/2023/06/image7.jpg)
Possibility of Combination Therapy
![](https://redarrowtx.com/wp-content/uploads/2023/06/icon1.png)
Cytokines could enhance treatment effect in ICI non-responders: 80% of solid tumor patients
![](https://redarrowtx.com/wp-content/uploads/2023/06/icon2.png)
NCM will be developed as monotherapy with possible applications for combination therapy with ICI
ICI: Immuno-checkpoint inhibitors